engleski

Expression of XOX-A9 in acute leukemia

In this study the expression pattern of HOXA9 in cell samples collected from patients with hematological malignancies was investigated. By using RT-PCR we analyzed the expression of HOXA9 in 36 AL samples (14 AML, 12 ALL and 10 mixed or biphenotypic AL - BAL), 4 B-CLL, several leukemia cell lines (K562, HL60, SU-DHL4 and NALM-6) as well as in control samples from healthy donors (peripheral blood and bone marrow mononuclear cells, PBMNC and BMMNC, respectively). In contrast to PBMNC, HOXA9 was found in bone marrow MNC of a healthy donor. In acute leukemia, HOXA9 was expressed in 79% (11/14) of AML, 60% (6/10) of BAL and, the most interesting finding, in 15% (2/12) of ALL samples. In relation to FAB and/or immunophenotype, HOXA9 was present in 1/2 FAB-M1, 2/4 FAB-M2, 2/2 FAB-M3, 3/3 FAB-M4, 2/2 FAB-M5a and in one FAB-unclassified MPO+CD13+ AL. Among ALL patients, HOXA9 was expressed in 0/4 T-ALL, 1/1 pro-B, 0/6 "common" -ALL, and 1/1 B-ALL whereas in biphenotypic AL the HOXA9 message was present in 1/1 FAB-M1, 0/2 FAB-M5a, 2/4 FAB-L2, 2/2 FAB-UAL and in 1/1 biclonal BAL. Among the cell lines tested, HOXA9 was found in cells with myeloid differentiation (HL60 and K562), but also in pre-B cell line NALM6. Although preferentially expressed in leukemic cells with myeloid commitment, the expression of HOXA9 in B-lineage ALL is consistent with its finding in pre-B cell line NALM6. Further studies are needed to correlate leukemia HOXA9 gene expression with biological and clinical behaviour of AL.

HOXA9; acute leukemia

nije evidentirano